We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Ammonia Predicts Prognosis in Hepatitis B Virus‐Related Liver Failure

By LabMedica International staff writers
Posted on 24 Sep 2020
Print article
Image: The Vitros 350 clinical chemistry system (Photo courtesy of Ortho Clinical Diagnostic).
Image: The Vitros 350 clinical chemistry system (Photo courtesy of Ortho Clinical Diagnostic).
Acute‐on‐chronic liver failure (ACLF) is the rapid deterioration of liver function in chronic liver disease often associated with the development of serious complications such as hepatorenal syndrome and hepatic encephalopathy within a short period of time.

Hepatic encephalopathy (HE) is a common feature of acute liver failure and has been reported to be associated with poor outcomes. Ammonia is thought to be central to the pathogenesis of HE, but its role in hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF) is unclear.

Clinical Laboratorians at the Zhejiang University (Hangzhou, China) recruited all 127 patients with HBV‐ACLF, defined as total bilirubin (TBIL) ≥ 205 μmol/L and international normalized ratio (INR) ≥ 1.5 according to COSSH‐ACLF criteria, who were treated at their institution between July 2018 and February 2020 for a retrospective study.

Laboratory parameters included total protein, albumin, alanine aminotransferase, aspartate aminotransferase, creatinine, TBIL, arterial ammonia, INR, white blood cell count, platelet count, and blood urea nitrogen. Arterial ammonia was estimated within 24 hours of admission using a Vitros 350 dry chemistry system (Ortho Clinical Diagnostic, Rochester, NY, USA) in heparinized plasma.

The scientists reported that the median ammonia level at enrollment was 55.0 (interquartile range, 36.0‐76.0) and 77 patients (60.6%) had high ammonia at the time of admission. Ammonia level was found to be positively correlated to model for end-stage liver disease (MELD) score and COSSH‐ACLF score. In the study population, there were 61 patients with cirrhosis and 66 patients without cirrhosis. No significant difference between the two groups except that the age of the cirrhosis group was higher than that of the non‐cirrhosis group.

Among the 127 participants, 87 survived and 40 died, representing a 28‐day mortality rate of 31.5%. The mean MELD score, TBIL, INR, white blood cell count, ammonia, and COSSH‐ACLF score were higher among non‐surviving participants; however, the mean age, gender ratio, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, creatinine, blood urea nitrogen, and platelet count were not significantly different between survivors and non‐survivors. Dividing patients according to the ammonia cut‐off value of 73 μmol/L revealed higher ammonia level to be associated with higher alanine aminotransferase, INR, mortality rate, COSSH‐ACLF score and MELD score.

The authors concluded that their results suggest that high ammonia level at admission is an independent factor for predicting short‐term mortality in patients with HBV‐ACLF. Therefore, ammonia levels may represent a therapeutic target for this condition. The study was published on September 11, 2020 in the Journal of Clinical Laboratory Analysis.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.